Peptide injection site reaction: infection and vial evidence
Peptide injection site reaction and infection have not been measured in published infection-rate studies of people injecting peptides specifically.
The nearest vial evidence is a black-market androgen culture study.
The nearest peptide-vial test purchase is a semaglutide study.
The nearest human symptom denominator is a survey of men injecting image- and performance-enhancing drugs.
The vial findings were mixed.
Most unused androgen products in the 2025 culture study were free of bacterial contamination.
One unused item was culture-positive.
No participant developed an injection-related infection linked to a contaminated product.
For the wider vial-quality question, see what is actually in the vial.
For phone numbers and published cases around symptoms, see when to get help.
For what a certificate can and cannot prove, see certificate of analysis.
What has been measured in vials?
The closest vial-culture study asked people in the Netherlands to submit black-market androgen products.
The researchers cultured the products for aerobic and anaerobic bacteria.
The sample contained 63 products from 31 participants.
Every product was oil-based.
Inclusion required a product containing at least 1 mL of oil.
The sample included 41 unused ampules or multidose vials.
One unused item was contaminated.
The authors report that as 2%.
The sample included 22 multidose vials that were already in use.
Two used vials were contaminated.
The authors report that as 9%.
Both contaminated used vials came from the same participant.
The organisms identified were Bacillus species, Staphylococcus epidermidis, Staphylococcus warneri, Staphylococcus saprophyticus and Micrococcus luteus.
No participant developed an injection-related infection linked to contaminated products.
Source, claim date 20 August 2026: Verdegaal TJ et al., Harm Reduction Journal 2025, PMID 41350877, DOI 10.1186/s12954-025-01359-w.
How can the same study point in two directions?
The clean-vial finding matters.
The authors state that the majority of unused androgen products was free of bacterial contamination.
They say this may reflect reasonably hygienic manufacturing, or properties of oil-based androgen products that suppress bacterial growth.
They name benzyl alcohol, low water content and high carrier-oil viscosity as possible factors.
The contaminated-vial finding also matters.
The authors state that live bacteria were detected in both used and unused products.
They say that exposure to contaminated androgen products may be more common than previously acknowledged.
Both readings belong together because they come from the same 63 products.
Did the symptoms and culture results line up?
Some participants reported persistent muscle pain and swelling from products that tested clean.
The participant who supplied the two positive used multidose vials reported no symptoms from those products.
The authors also state that infection after androgen injection does not by itself prove that the product was contaminated.
They name skin bacteria introduced at the injection site as one possible source.
They also name bacteria reaching post-injection tissue injury from elsewhere in the body as another possible source.
What limits apply to the vial figures?
The sample size was modest.
The authors state that this prevents precise estimation of the true contamination prevalence in black-market androgens.
Product donation was voluntary.
The authors state that selection bias cannot be excluded.
Unused multidose vials were harder to obtain because donated products were not returned.
No reimbursement was offered for donated products.
All participants who donated products were enrolled in a harm-reduction intervention.
That intervention covered product contamination and general injection hygiene.
The authors state that increased vigilance may have lowered the contamination prevalence they observed.
They also state that the magnitude of that influence cannot be determined without a non-intervention control group.
These limits are part of the result.
They do not erase the clean-vial finding.
They do not erase the contaminated-vial finding.
Why is sterile not the same as endotoxin-free?
A separate published test-purchase study obtained semaglutide products from online sellers without a prescription.
Three vials arrived.
Those three vials were tested for viable microorganisms.
No viable microorganisms were found in the three lyophilised peptide samples at the time of testing.
Endotoxin was detected in all three samples.
The measured endotoxin range was 2.1645 EU/mg to 8.9511 EU/mg.
One vial was described by the authors as having an elevated endotoxin level.
Those results show why sterility and endotoxin are separate checks.
A sterility test asks whether viable microorganisms are present.
An endotoxin test asks whether bacterial endotoxin is present.
Source, claim date 20 August 2026: Journal of Medical Internet Research 2024, PMID 39509151, DOI 10.2196/65440.
Removing endotoxin is called depyrogenation.
A 2025 Journal of Pharmaceutical Sciences paper tested sterilization and depyrogenation conditions for closed ampoules.
The paper used dry heat at 250 C for 30 minutes.
The paper reports endotoxin removal at 350 C to 550 C under the tested holding-stage conditions.
The paper also reports endotoxin removal at 300 C with an exposure time of 200 seconds.
The paper is about ampoule manufacturing.
It is not a study of grey-market peptide vials.
Source, claim date 20 August 2026: Rashed AM et al., Journal of Pharmaceutical Sciences 2025, PMID 40122208, DOI 10.1016/j.xphs.2025.103769.
The precise word for a product that can cause fever through pyrogen content is pyrogenic.
Pyrogenic is not the same word as non-sterile.
What did people injecting IPEDs report?
The nearest human denominator study surveyed 366 men who injected image- and performance-enhancing drugs.
The paper was published in 2015.
The study was conducted in the United Kingdom.
The symptoms were self-reported.
They were not clinician-diagnosed infections.
Image- and performance-enhancing drug use is dominated by anabolic steroids.
That population overlaps with this site's readers.
It is not a peptide-user population.
Source, claim date 20 August 2026: Hope VD et al., Epidemiology and Infection 2015, PMID 24713416, DOI 10.1017/s0950268814000727.
| Self-reported injection-site problem | Finding in Hope 2015 |
|---|---|
| Ever had redness, swelling and tenderness | 42% |
| Redness, swelling and tenderness in the preceding year | 36% |
| Ever had an abscess or open wound | 6.8% |
The same survey asked about treatment among the men who reported each symptom.
The treatment denominators are not all 366 men.
The redness, tenderness and swelling denominator is 155 men.
The abscess, sore or open wound denominator is 25 men.
| Had ever had treatment | Redness, tenderness and swelling (155 men) | Abscess, sore or open wound (25 men) |
|---|---|---|
| Yes | 27 men, reported as 17% | 19 men, reported as 76% |
Table 3 also reports where treatment came from.
People could name more than one source.
The columns therefore total more than 100%.
| Source of treatment | Of the 27 men | Of the 19 men |
|---|---|---|
| General Practitioner | 59% | 32% |
| Accident and Emergency or walk-in clinic | 48% | 47% |
| Self-treatment | 48% | 26% |
| Needle-and-syringe programme | 22% | 5% |
| Other source | 22% | 0% |
The 17% figure means ever had treatment.
Self-treatment counts toward that figure.
It does not mean 17% asked another person for treatment.
The share who asked another person cannot be computed exactly from Table 3 because sources overlap.
What limits apply to the IPED survey?
The authors state that the representativeness of the recruited participants is impossible to measure.
The authors state that their recruitment method was established for people who inject drugs.
They also state that the robustness of that recruitment method is not known for people who inject IPEDs.
The authors state that the findings rely on self-report.
They advise caution when generalising the findings to the wider population of IPED injectors.
Three quarters of the men had ever visited a needle-and-syringe programme site.
The paper gives the count as 274 of 366 men.
The authors state that this reflects recruitment through those services.
Why are PWID infection rates not peptide rates?
A 2025 systematic review and meta-analysis pooled injection-related infection studies among people who inject drugs.
It included 87 eligible studies.
The studies covered 25 countries.
The pooled skin and soft-tissue infection estimate was 13% in the past month.
The 13% estimate had a 95% CI of 9% to 19%.
The pooled estimate was 30% in the past 3 to 12 months.
The 30% estimate had a 95% CI of 23% to 37%.
The pooled lifetime estimate was 47%.
The 47% estimate had a 95% CI of 29% to 66%.
Source, claim date 20 August 2026: Wheeler A et al., Open Forum Infectious Diseases 2025, PMID 40160341, DOI 10.1093/ofid/ofaf108.
Those numbers are not peptide-user rates.
The population in that review is people who inject drugs.
The review's own limitations matter here.
Most prevalence studies were conducted in high-income countries.
Many recruited through needle-syringe programmes, harm-reduction services, drug-treatment services or mixed service settings.
The authors state that contact with health services may affect generalisability.
They also state that definitions of injection-related infection varied between studies.
Every severe-infection estimate in the review came from high-income countries.
The authors call that a key data gap.
The 47% lifetime figure is printed here so it is not silently imported into a peptide page.
What did Europe PMC not show for peptides?
The Europe PMC query set below did not identify a published infection-rate study for people injecting peptides specifically.
That is a statement about the query result, not proof that no such study exists.
| Europe PMC query, claim date 20 August 2026 | Hits |
|---|---|
(peptide OR peptides) AND ("injection site" OR "injecting") AND (infection OR abscess OR cellulitis) | 31,824 |
("injection site infection" OR "injecting site infection") AND (peptide OR peptides OR "growth hormone secretagogue") | 34 |
(BPC-157 OR "TB-500" OR CJC-1295 OR ipamorelin OR "melanotan") AND (infection OR abscess OR cellulitis OR sepsis) | 398 |
One close result is PMID 41204776.
It studied 30 people who inject image- and performance-enhancing drugs.
It used qualitative focus groups and semi-structured interviews.
It explored injection practices and safety strategies.
It is not a measurement of infection rates.
It is not peptide-specific.
Source, claim date 20 August 2026: Piatkowski T et al., Health (London) 2026, PMID 41204776, DOI 10.1177/13634593251388294.
What do all three measurement sources have in common?
The Verdegaal vial study recruited people enrolled in a harm-reduction intervention.
That intervention covered product contamination and injection hygiene.
The Hope survey recruited through health services.
The Hope paper states that 274 of 366 men had ever visited a needle-and-syringe programme site.
The Wheeler review pooled studies conducted among people who inject drugs.
Many of those studies recruited through services.
This matters because service contact is part of the sample shape.
None of the three sources measures how the figures would change in people outside those services.
The page therefore reports the figures as measured.
It does not adjust them.
What do these studies not prove?
They do not prove that the vial-culture percentages apply to peptide vials.
The Verdegaal products were oil-based androgens.
They do not prove that a sterile vial is endotoxin-free.
The semaglutide test purchase found no viable microorganisms and detected endotoxin in the same three vials.
They do not prove that IPED symptom rates are peptide symptom rates.
The Hope survey is the nearest human denominator we found, and it is still an adjacent population.
They do not prove that the Wheeler pooled PWID rates apply to people injecting peptides.
The Wheeler population, exposure pattern and recruitment settings are different.
The useful answer is narrower.
Published evidence shows that vial sterility is one question.
Published evidence shows that endotoxin content is a separate question.
Published evidence shows that culture-positive contamination is a separate question.
Published evidence shows that self-reported injection-site symptoms are a separate question.
Return to the shared risk evidence overview to choose among vial, certificate, calculation and symptom questions.